Dermata Therapeutics Inc Share Price Today: Live Updates & Key Insights

Dermata Therapeutics Inc share price today is $1.31, up 20.66%. The stock opened at $1.49 against the previous close of $1.21, with an intraday high of $1.84 and low of $1.37.

Dermata Therapeutics Inc Share Price Chart

Dermata Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Dermata Therapeutics Inc Share Price Performance

$1.31 0.2066(20.66%) DRMA at 23 Mar 2026 12:45 PM Biotechnology
Lowest Today 1.37
Highest Today 1.84
Today’s Open 1.49
Prev. Close 1.21
52 Week High 14.60
52 Week Low 1.11
Day’s Range: Low 1.37 High 1.84
52-Week Range: Low 1.11 High 14.60
1 day return -
1 Week return +17.35
1 month return +13.6
3 month return -35.45
6 month return -73.99
1 year return +8.39
3 year return -93.03
5 year return -99.88
10 year return -

Dermata Therapeutics Inc Institutional Holdings

UBS Group AG 0.35

Fidelity Extended Market Index 0.21

Tower Research Capital LLC 0.07

Fidelity Series Total Market Index 0.04

SBI Securities Co Ltd 0.00

Bank of America Corp 0.00

Armistice Capital, LLC 0.00

Geode Capital Management, LLC 0.00

JONES FINANCIAL COMPANIES LLLP 0.00

Dermata Therapeutics Inc Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Dermata Therapeutics Inc Fundamentals

Market Cap 4.67 M

PB Ratio 1.0375

PE Ratio 0.0958

Enterprise Value -0.56 M

Total Assets 3.53 M

Volume 39595091

Dermata Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-7330319 -7.3M, FY22:-9610913 -9.6M, FY21:-7948090 -7.9M, FY20:-3433799 -3.4M, FY19:-4972104 -5.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-1691989 -1.7M, Q2/2025:-1701093 -1.7M, Q1/2025:-2303587 -2.3M, Q3/2024:-3173156 -3.2M, Q2/2024:-2829106 -2.8M

About Dermata Therapeutics Inc & investment objective

Company Information Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 8

Industry Biotechnology

CEO Mr. Gerald T. Proehl

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Dermata Therapeutics Inc FAQs

What is the share price of Dermata Therapeutics Inc today?

The current share price of Dermata Therapeutics Inc is $1.31.

Can I buy Dermata Therapeutics Inc shares in India?

Yes, Indian investors can buy Dermata Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Dermata Therapeutics Inc shares in India?

You can easily invest in Dermata Therapeutics Inc shares from India by:

Can I buy fractional shares of Dermata Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Dermata Therapeutics Inc?

Dermata Therapeutics Inc has a market cap of $4.67 M.

In which sector does Dermata Therapeutics Inc belong?

Dermata Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Dermata Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Dermata Therapeutics Inc?

The PE ratio of Dermata Therapeutics Inc is 0.10 and the PB ratio is 1.04.